OWLT Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of -12425.36%. Owlet, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 28.01%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 354.16%. Given that Perspective Therapeutics, Inc. has higher upside potential than Owlet, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.706, which suggesting that the stock is 70.642% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Owlet, Inc.'s net income of $4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.22x versus 183.75x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 6.19%. Owlet, Inc.'s return on equity of -- beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 28.01%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 64.16%. Given that InfuSystem Holdings, Inc. has higher upside potential than Owlet, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.706, which suggesting that the stock is 70.642% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Owlet, Inc.'s net income of $4M is higher than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.22x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nephros, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 7.07%. Owlet, Inc.'s return on equity of -- beat Nephros, Inc.'s return on equity of 16.22%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 28.01%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 39.49%. Given that Nephros, Inc. has higher upside potential than Owlet, Inc., analysts believe Nephros, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.706, which suggesting that the stock is 70.642% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.407, suggesting its more volatile than the S&P 500 by 40.722%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Owlet, Inc.'s net income of $4M is higher than Nephros, Inc.'s net income of $337K. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 33.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.22x versus 2.80x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 12.58% compared to Owlet, Inc.'s net margin of 3.93%. Owlet, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Owlet, Inc. has a consensus price target of $17.00, signalling upside risk potential of 28.01%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 141.12%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Owlet, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Owlet, Inc..

Owlet, Inc. has a beta of 1.706, which suggesting that the stock is 70.642% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Owlet, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Owlet, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Owlet, Inc. quarterly revenues are $32M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Owlet, Inc.'s net income of $4M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Owlet, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Owlet, Inc. is 2.22x versus 0.68x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.